Gemdo Warning Letter Speaks Volumes About FDA Concerns, Industry Challenges
This article was originally published in The Rose Sheet
Executive Summary
There is much for cosmetic stakeholders to take away from FDA’s April 16 warning letter to Gemdo Cosmetics Inc., which highlights some key enforcement priorities at the agency and topline issues currently facing the industry as a whole.